OncoResponse Reports Phase 1 Findings of OR502, an anti-LILRB2 Antibody, in Patients with Advanced Cancer.

Eteplirsen, developed by Sarepta Therapeutics, is an antisense oligonucleotide that targets the dystrophin gene.

Harbour BioMed has filed an IND application for HBM9378/SKB378 to treat chronic obstructive pulmonary disease.

Elacestrant hydrochloride is a small molecule drug that targets ERα and is used in the treatment of various therapeutic areas.

SystImmune, Inc. has received FDA approval for the IND application of BL-M17D1 targeting advanced solid tumors.

Cetuximab is a chimeric monoclonal antibody that targets the epidermal growth factor receptor (EGFR).

Nammi Therapeutics, Inc. has reported the first patient has received QXL138AM in a Phase 1 trial focused on advanced solid tumors and multiple myeloma.

Orforglipron is a small molecule drug that targets the GLP-1R, with therapeutic applications in Nervous System Diseases.

Pheast Shares Latest Preclinical Findings on PHST001, an Anti-CD24 Checkpoint Inhibitor for Macrophages, at SITC 2024.

Eplontersen, is an antisense oligonucleotide developed by Ionis Pharmaceuticals and Akcea Therapeutics.

Radella Pharmaceuticals reveals preliminary results from the Phase 1a trial of MD-18, a groundbreaking peptide aimed at PTP1B to combat obesity.

IWY-357 is a small molecule drug developed by Novartis AG, with a focus on the therapeutic area of infectious diseases.